Daniel Chen

Partner & Co-Founder Genesis BioCapital

A pioneer in the field of cancer immunotherapy and protein engineering and co-author of the Cancer Immunity Cycle, Dr. Chen is an experienced physician-scientist, key opinion leader, drug developer, and entrepreneur. Dr. Chen spent over a decade at Genentech, as Vice President and Global Head of Cancer Immunotherapy Development, where he focused on development of immune modulatory, anti-angiogenic, and ADCs as targeted therapies and their accompanying diagnostic tools. This included leading clinical development for atezolizumab (TECENTRIQ), the first approved PD-L1 inhibitor, from pre-IND to clinical trials and commercialization. Dr. Chen then joined IGM Biosciences as Chief Medical Officer, developing novel engineered multivalent and multispecific therapeutics and overseeing the company’s growth from a small 25-person team to one of the most successful IPOs of 2019. He is also a founding partner of Genesis BioCapital and founder and CEO of Synthetic Design Lab.

Seminars

Tuesday 24th February 2026
Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies
8:00 am
  • Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
  • Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
  • Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
  • Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design
Tuesday 24th February 2026
Chair:
Daniel Chen Speaker Photo - 16th World ADC London Summit